- Temozolomide
- Bevacozumab
- carmustine
- Radiosensitizers
- Others
Glioblastoma Multiforme Treatment Market size was valued at USD 2.85 billion in 2023 and is poised to grow at a CAGR of 9.9% from 2024-2030. Glioblastoma multiforme contains the complexly differentiated neoplastic astrocytes which are the subtype of the central nervous system. Glioblastoma multiforme is different from the anaplastic astrocytoma due to the presence of hyperplastic blood vessels and necrotic tissue. The glioblastoma multiforme is diagnosed by using the imaging modules namely, positron emission tomography (PET), magnetic resonance imaging (MRI), and computed tomography (CT). Glioblastoma multiforme is classified into two types namely, gliosarcoma and giant cell glioblastoma. Gliomas are tumors that emerge from glial cells and might occur in the brain or the spinal cord. The common symptoms observed in patients suffering from glioblastoma multiforme include nausea, headache, seizure, memory loss, and hemiparesis, among others. The increase in alcohol consumption, a rise in malaria prevalence, and the increase in the incidence of seizures are the key factors driving the global glioblastoma multiforme treatment market. Furthermore, an increase in research and development in gene therapy, molecular biotechnology for the treatment of CNS-associated disorders, urgent need for alternative treatment procedures due to the resistance of glioma cells to conventional therapies are anticipated to boost the glioblastoma multiforme treatment over the forecast period. However, major restraints of the glioblastoma multiforme treatment are current treatment therapies such as radiation and chemotherapy do not prevent tumor recurrence that causes death in glioblastoma multiforme patients. Similarly, high expenditure for genomics-based research, less number of drugs available in the market, and the high cost of treatment are expected to hinder the glioblastoma multiforme treatment market growth over the forecast period.
Global Glioblastoma Multiforme Treatment Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
9.9%
Largest Market
North-America
Fastest Growing Market
Asia pacific
Glioblastoma Multiforme Treatment Market Dynamics
Increase in prevalence of brain tumours (According to U.S. National Cancer Institute (NCI) glioblastoma multiforme is considered as the most aggressive form of brain cancer with 15.4% of all primary brain tumours and about 60% 75% of all astrocytoma) driving the growth of glioblastoma multiforme treatment market. Moreover, various drugs under clinical trials like CDX-110 (manufactured by Celldex Therapeutics) (Phase 3) and DCVax (Northwest Biotherapeutics) (Phase 3) expected to fuel growth of the market. Rising product approvals from U.S. Food and Drug Administration (FDA) also expected to drive revenue of glioblastoma treatment market. For instance, in March 2005, U.S. Food and Drug Administration (FDA) approved temozolomide (Temodar) capsules, developed by Schering Corporation (Merck & Co., Inc.) to treat newly diagnosed patients with glioblastoma multiforme disease associated with radiotherapy and then as maintenance treatment. Similarly, entry of generics into the market also increases the growth of glioblastoma multiforme treatment.
North-America Got Significant Share
Glioblastoma Multiforme Treatment Market Regional Analysis
Geographically, the glioblastoma multiforme treatment market is segmented into the following regions Viz. North America, Asia-Pacific, Europe, Middle East & Africa, and Latin America. North America dominates the glioblastoma multiforme treatment market followed by Europe and Asia-Pacific North American region growth is attributed to an increase in the prevalence of glioblastoma multiforme disease (According to Centres for Disease Control and Prevention (CDC), in 2011, approximately 22,000 adults in the U.S. were diagnosed with primary malignant tumours of the brain and spinal cord out of which gliomas accounted for the highest rate of incidence), investments in research and development, and increasing CNS cancers in the ageing population. Companies betting heavily on research activities due to a lack of drugs to treat glioblastoma multiforme in the market. Similarly, the National Brain Tumour Society, the Brain Tumour Foundation of Canada, and the American Brain Tumour Association are the health organizations engaged in raising awareness about glioblastoma multiforme leads to the growth of the glioblastoma multiforme treatment market over the forecast period. Europe glioblastoma multiforme treatment market revenue growth is driven by an increase in the geriatric population, a change in lifestyle and an increase in research and development activities by various pharmaceutical companies. Asia-Pacific is expected to be the fastest-growing market over the forecast period as a result of improving healthcare infrastructure, and rising awareness of glioblastoma multiforme treatment. Furthermore, extensive use of genomic profiling in bioinformatics technology by the research and development firms in the Asia-Pacific region is expected to drive the treatment market for nervous carcinoma by discovering new drug targets.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Global Glioblastoma Multiforme Treatment Market Segmentation
By Drug Type
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Geography
- North America
- Asia Pacific
- Europe
- Latin America
- MEA
Frequently Asked Questions
The glioblastoma multiforme treatment market size was valued at USD 2.85 billion in 2023
The glioblastoma multiforme treatment market key players are: Merck & Co Teva Pharmaceutical Industries Arbor Pharmaceuticals Sun Pharmaceutical Industries F. Hoffmann-Le Roche Abbvie Celldex Therapeutics Exellixis Bristol-Myers Squibb AstraZeneca GlaxoSmithKline CANbridge Life Sciences Apogenix Pfizer Vascular Biogenics
The glioblastoma multiforme treatment market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
1. Executive summary
2. Global Glioblastoma Multiforme Treatment Market Introduction
2.1. Global Glioblastoma Multiforme Treatment Market Taxonomy
2.2. Global Glioblastoma Multiforme Treatment Market Definitions
2.2.1. Drug Type
2.2.2. Distribution Channel
3. Global Glioblastoma Multiforme Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Glioblastoma Multiforme Treatment Market Dynamics Factors Impact Analysis
3.6. Global Glioblastoma Multiforme Treatment Market Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Glioblastoma Multiforme Treatment Market Product Innovations
4. Global Glioblastoma Multiforme Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. Global Glioblastoma Multiforme Treatment Market, By Drug Type, 2019 - 2023 and Forecast, 2024 - 2030
5.1. Temozolomide
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.3. Market Opportunity Analysis
5.2. Bevacozumab
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.3. Market Opportunity Analysis
5.3. Carmustine
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.3.3. Market Opportunity Analysis
5.4. Radiosensitizers
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.4.3. Market Opportunity Analysis
5.5. Others
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.5.3. Market Opportunity Analysis
6. Global Glioblastoma Multiforme Treatment Market Forecast, By Distribution Channel , 2019 - 2023 and Forecast, 2024 - 2030
6.1. Retail Pharmacies
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.3. Market Opportunity Analysis
6.2. Hospital Pharmacies
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
6.3. Online Pharmacies
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.3.3. Market Opportunity Analysis
7. Global Glioblastoma Multiforme Treatment Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030
7.1. North America
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.5.3. Market Opportunity Analysis
7.6. Global Glioblastoma Multiforme Treatment Market - Opportunity Analysis Index, By Drug Class, Distribution Channel and Region, 2024 - 2030
8. North America Glioblastoma Multiforme Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
8.1. Drug Class Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Temozolomide
8.1.2. Bevacozumab
8.1.3. carmustine
8.1.4. Radiosensitizers
8.1.5. Others
8.2. Distribution Channel Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
8.2.1. Retail Pharmacies
8.2.2. Hospital Pharmacies
8.2.3. Online Pharmacies
8.3. Country Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1. U.S.
8.3.2. Canada
8.4. North America Glioblastoma Multiforme Treatment Market - Opportunity Analysis Index, By Drug Analysis, Distribution Channel, and Country, 2024 - 2030
8.5. North America Glioblastoma Multiforme Treatment Market Dynamics Trends
9. Europe Glioblastoma Multiforme Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
9.1. Drug Class Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Temozolomide
9.1.2. Bevacozumab
9.1.3. carmustine
9.1.4. Radiosensitizers
9.1.5. Others
9.2. Distribution Channel Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Retail Pharmacies
9.2.2. Hospital Pharmacies
9.2.3. Online Pharmacies
9.3. Country Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Russia
9.3.7. Poland
9.3.8. Rest of Europe
9.4. Europe Glioblastoma Multiforme Treatment Market - Opportunity Analysis Index, By Drug Analysis, Distribution Channel and Country, 2024 - 2030
9.5. Europe Glioblastoma Multiforme Treatment Market Dynamics Trends
10. Asia-Pacific Glioblastoma Multiforme Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
10.1. Drug Class Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Temozolomide
10.1.2. Bevacozumab
10.1.3. carmustine
10.1.4. Radiosensitizers
10.1.5. Others
10.2. Distribution Channel Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Retail Pharmacies
10.2.2. Hospital Pharmacies
10.2.3. Online Pharmacies
10.3. Country Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Japan
10.3.2. China
10.3.3. India
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Glioblastoma Multiforme Treatment Market - Opportunity Analysis Index, By Drug Analysis, Distribution Channel and Country, 2024 - 2030
10.5. Europe Glioblastoma Multiforme Treatment Market Dynamics Trends
11. Latin America Glioblastoma Multiforme Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
11.1. Drug Class Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Temozolomide
11.1.2. Bevacozumab
11.1.3. carmustine
11.1.4. Radiosensitizers
11.1.5. Others
11.2. Distribution Channel Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Retail Pharmacies
11.2.2. Hospital Pharmacies
11.2.3. Online Pharmacies
11.3. Country Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Venezuela
11.3.5. Rest of Latin America
11.4. Latin America Glioblastoma Multiforme Treatment Market - Opportunity Analysis Index, By Drug Analysis, Distribution Channel and Country, 2024 - 2030
11.5. Latin America Glioblastoma Multiforme Treatment Market Dynamics Trends
12. Middle East and Africa Glioblastoma Multiforme Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
12.1. Drug Class Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Temozolomide
12.1.2. Bevacozumab
12.1.3. carmustine
12.1.4. Radiosensitizers
12.1.5. Others
12.2. Distribution Channel Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Retail Pharmacies
12.2.2. Hospital Pharmacies
12.2.3. Online Pharmacies
12.3. Country Analysis (2019 - 2023) and Forecast (2024 - 2030) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Gulf Cooperation Council (GCC) Countries
12.3.2. Israel
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Glioblastoma Multiforme Treatment Market - Opportunity Analysis Index By Drug Analysis, Distribution Channel and Country, 2024 - 2030
12.5. MEA Glioblastoma Multiforme Treatment Market Dynamics Trends
13. Competition Landscape
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Pfizer, Inc. (U.S)
13.2.2. Allergan Inc. (Ireland)
13.2.3. Boehringer Ingelheim GmbH (Germany)
13.2.4. CIBA Vision Ophthalmics (U.S)
13.2.5. Sanofi (France)
13.2.6. Novartis AG (Switzerland)
13.2.7. Bausch & Lomb Inc. (Valeant) (Canada)
13.2.8. Merck & Co., Inc. (U.S)
13.2.9. Santen Pharmaceuticals Co. Ltd.(Japan)
14. Research Methodology
15. Key Assumptions and Acronyms
- Merck & Co
- Teva Pharmaceutical Industries
- Arbor Pharmaceuticals
- Sun Pharmaceutical Industries
- F. Hoffmann-Le Roche
- Abbvie
- Celldex Therapeutics
- Exellixis
- Bristol-Myers Squibb
- AstraZeneca
- GlaxoSmithKline
- CANbridge Life Sciences
- Apogenix
- Pfizer
- Vascular Biogenics